로딩 중…
지수 로딩 중…
HLB INC.
028300· KOSDAQ· Health Care· Health Care Equipment & Services
₩46,050-2.85%
2026-10-07
Financials
Valuation Metrics
HLB INC.'s Market Cap is ₩6.1T. At end of 2025 it was ₩6.8T. Ranked #98 of 2,419 in KR market (top 4%), #10 of 1,638 on KOSDAQ (top 0.6%), #1 of 95 in Health Care Equipment & Services (top 1%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 6.13T KRW | KR#98/2,419 Sec#1/95 |
| Revenue | 97.47B KRW | KR#1,431/2,419 Sec#38/95 |
| Net Income | -227.03B KRW | KR—/2,419 Sec—/95 |
| Total Assets | 907.98B KRW | KR#505/2,419 Sec#6/95 |
| Net Assets | 422.44B KRW | KR#576/2,419 Sec#8/95 |
| Employees | 168 | KR#1,227/2,419 Sec#40/95 |
| Value | ||
| P/B | 14.52x | KR#2,384/2,419 Sec#93/95 |
| P/S | 62.93x | KR#2,374/2,419 Sec#94/95 |
| FCF Yield | -1.79% | KR—/2,419 Sec—/95 |
| Profitability | ||
| ROE | -53.74% | KR#2,286/2,419 Sec#87/95 |
| ROA | -25.00% | KR#2,281/2,419 Sec#84/95 |
| Op. Margin | -100.66% | KR#2,299/2,419 Sec#84/95 |
| Revenue Growth | 28.97% | KR#402/2,419 Sec#21/95 |
| Financial Health | ||
| Debt Ratio | 114.94% | KR#1,675/2,419 Sec#82/95 |
| FCF | -109.53B KRW | KR#2,138/2,419 Sec#84/95 |
| Cash | 26.38B KRW | KR#1,083/2,419 Sec#28/95 |
| Current Ratio | 0.26x | KR#2,218/2,419 Sec#93/95 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,419 Sec—/95 |
| Performance | ||
| 1Y Return | 21.18% | KR#443/2,419 Sec#12/95 |
| 1M Return | 39.76% | KR#102/2,419 Sec#6/95 |
| From 52W High | -33.45% | KR#722/2,419 Sec#25/95 |
| 1Y MDD | -62.39% | KR#1,618/2,419 Sec#56/95 |
| Trading | ||
| Volume | 991,036 shares | KR#109/2,419 Sec#6/95 |
| Trading Value | 46.06B KRW | KR#89/2,419 Sec#3/95 |
| Foreign Own. | 17.75% | KR#261/2,419 Sec#6/95 |
| Per Share | ||
| EPS | -1,704 KRW | KR—/2,419 Sec—/95 |
| BPS | 3,172 KRW | KR#1,832/2,419 Sec#58/95 |
Company Info
동사는 1985년 설립돼 1996년 코스닥에 상장한 바이오 의약품 회사로, 2023년 선박사업부를 물적분할해 HLB이엔지를 설립함. 헬스케어사업부는 체외진단 의료기기, 의약외품, 의료소모품을 제조·판매하고, Elevar와 Immunomic Therapeutics는 항암제 및 면역치료제를 개발하고 있음. 동사는 첨단 바이오 연구소 설립, 리보세라닙 치료제 FDA 승인 추진 등 혁신신약 개발로 글로벌 성장하고 있음. HLB는 1985년에 설립되었으며 세종특별자치시 연동면에 본사를 두고 있습니다.